3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Stomach Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Adenocarcinoma
3
Lung Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Neoplasm Metastasis
1
Metastatic Gastric Adenocarcinoma
1
Liver Neoplasms
1
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
1
Gastroesophageal Junction Adenocarcinoma
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Interventions
Gemcitabine
12
Mitomycin
11
Cisplatin
10
Carboplatin
8
pembrolizumab
7
Docetaxel
4
toripalimab
3
avelumab
3
atezolizumab
3
Paclitaxel
3
sacituzumab govitecan
2
disitamab vedotin
2
Taxes
2
Specimen Handling
2
Platinum
2
Magnetic Resonance Spectroscopy
2
Injections
2
1,2-diaminocyclohexaneplatinum II citrate
2
vinflunine
1
valrubicin
1
tislelizumab
1
lenvatinib
1
eribulin
1
epacadostat
1
enfortumab vedotin
1
durvalumab
1
dodecyl maltoside
1
Vitamin B 12
1
Standard of Care
1
Ramucirumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Transitional Cell
×
Ramucirumab
×
Clear all
NCT02426125
2023-08-21
RANGE
Eli Lilly and Company
Phase 3
Completed
530 enrolled
22 charts